According to BlockBeats, on June 5, the board of directors of Silo Pharma, a publicly traded pharmaceutical company, approved the purchase of Bitcoin worth no more than $1 million as a reserve asset. Silo Pharma CEO Eric Weisblum stated that incorporating Bitcoin into the company's reserves is a strategic decision to diversify assets through digital value storage and serves as a safeguard against inflation. Silo Pharma expects this move to optimize long-term shareholder value.